Sunnyvale, CA, ‐ October 31, 2019 ‐ JSR Life Sciences announced today that it has signed a technology licensing and joint development agreement with Dublin, Ireland-based GlycoSeLect, which provides recombinant prokaryotic lectins (RPLs) that enable the selective isolation of glycosylated biomolecules. The agreement will focus on the development of a glyco-affinity ligand and capture resin.
The RPL-based affinity ligand to be developed is aimed to be a generic affinity capture platform for glycosylated therapeutic proteins in a GMP-environment. The joint effort will target the development of a resin with high selectivity, high dynamic binding capacity and good chemical, especially caustic, resistance.
Under the terms of the agreement, JSR Life Sciences acquires the worldwide exclusive rights to a chemically and caustic stable RPL-based ligand from GlycoSeLect. The companies plan to jointly develop the ligand and resin, which will be manufactured by JSR Life Sciences, who will also assume global marketing, sales and distribution responsibilities. The commercial launch of the first RPL-based glyco-affinity resin is expected in 2‐3 years.
“As a broadly positioned service and materials provider for the Life Sciences industry, we are continually working on new technologies to satisfy unmet customer needs,” said Tim Lowery, president of JSR Life Sciences. “We see great potential for the RPL-based affinity resins and their impact on the purification of novel molecules in the bioprocessing industry.”
“The GlycoSeLect team is delighted to work with JSR Life Sciences, a progressive and innovative partner, to bring our RPL products to purification applications,” said Robert Dunne, CEO of GlycoSeLect. “GlycoSeLect is positioned to build on its validated RPL analytical applications and realize their potential for bioprocessing applications.”
About JSR Life Sciences, LLC
JSR Life Sciences, LLC is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, CA, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices in key markets throughout North America, Europe and Asia-Pacific.
GlycoSeLect Ltd is an early-stage BioTechnology company developing proprietary next-generation, highly specific and cost-efficient tools for the analysis, characterisation and purification of biotherapeutics. Spun-out from Dublin City University in 2013, GlycoSeLect specialises in the development of RPLs; enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules. GlycoSeLect’s RPLs target a wide range of glycoprofiles and are associated with market leading properties, including high affinity for glycan targets, high sensitivity of detection, high stability and robustness.
JSR Life Sciences, LLC
GlycoSeLect Ltd, Invent DCU, Glasnevin, Dublin 9, Ireland.
+353 87 7902652